122 related articles for article (PubMed ID: 2653407)
1. Use of the day 6 bone marrow to alter remission induction therapy in patients with acute myeloid leukaemia: a leukemia intergroup study.
Browman G; Preisler H; Raza A; Syracuse K; Azarnia N; Benger A; Chervenick P; D'Arrigo P; Doeblin T; Goldberg J
Br J Haematol; 1989 Apr; 71(4):493-7. PubMed ID: 2653407
[TBL] [Abstract][Full Text] [Related]
2. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
[TBL] [Abstract][Full Text] [Related]
3. Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinoside.
Preisler HD; Epstein J; Barcos M; Priore R; Raza A; Browman GP; Vogler R; Winton E; Grunwald H; Rai K
Br J Haematol; 1984 Sep; 58(1):19-32. PubMed ID: 6466567
[TBL] [Abstract][Full Text] [Related]
4. Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
Frassoni F; Labopin M; Powles R; Mary JY; Arcese W; Bacigalupo A; Bunjes D; Gluckman E; Ruutu T; Schaefer UW; Sierra J; Vernant JP; Willemze R; de Witte T; Gorin NC
Lancet; 2000 Apr; 355(9213):1393-8. PubMed ID: 10791522
[TBL] [Abstract][Full Text] [Related]
5. Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia.
De La Serna J; Francisco Tomás J; Solano C; García de Paredes ML; Campbell J; Grande C; Diaz-Mediavilla J
Leuk Lymphoma; 1997 Apr; 25(3-4):365-72. PubMed ID: 9168446
[TBL] [Abstract][Full Text] [Related]
6. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow biopsy during induction chemotherapy for acute myeloid leukaemia identifies only 50% of patients with resistant disease.
Roberts MM; Juttner CA; To LB; Kimber RJ
Leuk Res; 1988; 12(10):817-21. PubMed ID: 3199841
[TBL] [Abstract][Full Text] [Related]
8. Recognition of drug resistance during remission induction therapy for acute non-lymphocytic leukemia: utility of day 6 bone marrow biopsy.
Preisler H; Barcos M; Reese P; Priore RL; Pothier L
Leuk Res; 1983; 7(1):67-75. PubMed ID: 6572773
[TBL] [Abstract][Full Text] [Related]
9. Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients.
Stone RM; Maguire M; Goldberg MA; Antin JH; Rosenthal DS; Mayer RJ
Blood; 1988 Mar; 71(3):690-6. PubMed ID: 3422828
[TBL] [Abstract][Full Text] [Related]
10. Outcome assessment of age group-specific (+/- 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia.
Bassan R; Raimondi R; Lerede T; D'emilio A; Buelli M; Borleri G; Personeni A; Bellavita P; Rodeghiero F; Barbui T
Haematologica; 1998 Jul; 83(7):627-35. PubMed ID: 9718868
[TBL] [Abstract][Full Text] [Related]
11. Short term therapy (STT) for acute myelogenous leukaemia (AML).
Rohatiner AZ; Battista R; Bassan R; Love S; Oza AM; Whelan JS; Lim J; Buelli M; Viero P; D'Emillio A
Leukemia; 1992; 6 Suppl 2():85-8. PubMed ID: 1578952
[TBL] [Abstract][Full Text] [Related]
12. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups.
Zittoun RA; Mandelli F; Willemze R; de Witte T; Labar B; Resegotti L; Leoni F; Damasio E; Visani G; Papa G
N Engl J Med; 1995 Jan; 332(4):217-23. PubMed ID: 7808487
[TBL] [Abstract][Full Text] [Related]
13. Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation.
Sierra J; Brunet S; Grañena A; Olivé T; Bueno J; Ribera JM; Petit J; Besses C; Llorente A; Guardia R; Macía J; Rovira M; Badell I; Vela E; Díaz de Heredia C; Vivancos P; Carreras E; Feliu E; Montserrat E; Julía A; Cubells J; Rozman C; Domingo A; Ortega JJ
J Clin Oncol; 1996 Apr; 14(4):1353-63. PubMed ID: 8648394
[TBL] [Abstract][Full Text] [Related]
14. Changes in the characteristics of the bone marrow during therapy for acute non-lymphocytic leukemia: relationship to response to remission induction therapy.
Preisler HD; Raza A; Azarnia N; Rakowsky I; Barcos M; Browman G; Booker L; Goldberg J; Gottleib A; Brennan J
Eur J Cancer Clin Oncol; 1985 May; 21(5):563-71. PubMed ID: 3859416
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukaemia in first remission: a prospective controlled trial.
Conde E; Iriondo A; Rayon C; Richard C; Fanjul E; Garijo J; Hermosa V; Coma A; Bello C; Carrera D
Br J Haematol; 1988 Feb; 68(2):219-26. PubMed ID: 3280005
[TBL] [Abstract][Full Text] [Related]
16. Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group.
Cassileth PA; Andersen JW; Bennett JM; Harrington DP; Hines JD; Lazarus HM; Mazza JJ; McGlave PP; O'Connell MJ; Paietta E
Leukemia; 1992; 6 Suppl 2():116-9. PubMed ID: 1578910
[TBL] [Abstract][Full Text] [Related]
17. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission.
Stein AS; O'Donnell MR; Chai A; Schmidt GM; Nademanee A; Parker PM; Smith EP; Snyder DS; Molina A; Stepan DE; Spielberger R; Somlo G; Margolin KA; Vora N; Lipsett J; Lee J; Niland J; Forman SJ
J Clin Oncol; 1996 Aug; 14(8):2206-16. PubMed ID: 8708709
[TBL] [Abstract][Full Text] [Related]
18. Day-6 bone marrow aspirate for the prediction of response to remission induction therapy for acute myelogenous leukaemia.
Peters WG; Willemze R; Zwaan FE; Colly LP
Blut; 1988 Aug; 57(2):91-5. PubMed ID: 3165680
[TBL] [Abstract][Full Text] [Related]
19. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Giles F; O'Brien S; Cortes J; Verstovsek S; Bueso-Ramos C; Shan J; Pierce S; Garcia-Manero G; Keating M; Kantarjian H
Cancer; 2005 Aug; 104(3):547-54. PubMed ID: 15973664
[TBL] [Abstract][Full Text] [Related]
20. All-trans retinoic acid and low-dose cytosine arabinoside for the treatment of 'poor prognosis' acute myeloid leukemia.
Venditti A; Stasi R; Del Poeta G; Buccisano F; Aronica G; Bruno A; Pisani F; Caravita T; Masi M; Tribalto M
Leukemia; 1995 Jul; 9(7):1121-5. PubMed ID: 7630182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
